Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Dec-2016
Document Type: USP Monographs
DocId: GUID-F42E0DD1-0B7A-4D0D-985A-D4DD56B21B7F_1_en-US
DOI: https://doi.org/10.31003/USPNF_M386_01_01
DOI Ref: g8n6l

Atenolol Compounded Oral Solution

DEFINITION
Atenolol Compounded Oral Solution contains NLT 90.0% and NMT 110.0% of the labeled amount of atenolol ($C_{14}H_{22}N_2O_3$).

Prepare Atenolol Compounded Oral Solution at a 2-mg/mL concentration, for example, as follows (see *Pharmaceutical Compounding—Nonsterile Preparations* ⟨795⟩).

Atenolol	200 mg
Glycerin	5 mL
Vehicle for Oral Suspension	45 mL
Vehicle for Oral Solution, Sugar Free, a sufficient quantity to make	100 mL

Calculate the quantity of each ingredient required for the total volume and atenolol strength to be prepared. Mix the *Atenolol*, previously pulverized, and *Glycerin* to form a smooth paste. Incorporate the *Vehicle for Oral Suspension* or an equal volume of *Vehicle for Oral Solution, Sugar Free*. [Note—The *Vehicle for Oral Suspension* may be omitted.] Incorporate sufficient *Vehicle for Oral Solution, Sugar Free* in increments to bring to volume, and mix well. [Note—Do not use a sucrose-containing vehicle for oral solution.] Package, and label.

ADDITIONAL REQUIREMENTS
- **Packaging and Storage:** Package in amber, tight containers, and store at controlled room temperature.
- **Beyond-Use Date:** NMT 60 days after the day on which it was compounded when stored at controlled room temperature
- **Labeling:** Label it to state that it is to be shaken well before use, and to state the *Beyond-Use Date*.

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
ATENOLOL COMPOUNDED ORAL SOLUTION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	CMP2020 Compounding 2020

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 40(5)

Current DocID: GUID-F42E0DD1-0B7A-4D0D-985A-D4DD56B21B7F_1_en-US
DOI: https://doi.org/10.31003/USPNF_M386_01_01
DOI ref: g8n6l